biOasis Technologies Ord Shs V.BTI.H

RE:RE:Biosimilars. Worth thinking about...

[jdstox]

Thanks for your comments, BearDownAZ. 

You commented about my periphery statement that "xB3-001 already appears to be better in the periphery (the body) than Herceptin is, probably by virtue of the LRP-1 receptor and its presence pretty much everywhere that xB3-001 needs it to be."

I made that comment (with the cautionary word, "appears") for specific reasons.

First, better periphery performance of our platform (back in the days when it was MTf-TZM and/or MTfp-TZM) has been known for some years. What, to my knowledge, was not understood, and remains to be proved, is that the distribution of Transcend or xB3-based drugs may depend on the distribution of the LRP-1 receptor.

You're right that distribution does not equate to efficacy. However, improved peripheral efficacy in animal models was known to some degree before distribution was known, and LRP-1 may explain it. It's a very exciting thing that xB3-001 may be attracted to tumours by two receptors instead of just one. But you're right. Bioasis must prove all this in non-human primate studies and clinical trials before we can count on it (or anything else about xB3-001). 

But the major point I wanted to make is that the news is full of (or littered with) reports of improvements to Herceptin, some of them biosimilars, and others, drugs like Kadcyla and margetuximab. We're going to read about this stuff as all the players position themselves to get the best share they can of the upcoming, wide open, Herceptin-expired-patent market. Well, we may also have a drug that is an improvement over Herceptin in the periphery. And it crosses the BBB. We can justify high hopes for enhanced peripheral efficacy. There's no reason to fear evey biosimilar that comes along. We're not a biosimilar. We're possibly a real biobetter, a biosupperior, we think, we hope. Time will tell.

jdstox